The Spain Precision Medicine Market reached USD 1.41 Billion in 2024 and is projected to grow to USD 4.18 Billion by 2033, exhibiting a strong CAGR of 11.87% during 2025–2033. Growth is driven by major government investments in healthcare innovation, advancements in genomics, and a strong pharmaceutical sector accelerating the development of personalized treatment solutions across the country.
Study Assumption Years
- Base Year: 2024
- Historical Period: 2019–2024
- Forecast Period: 2025–2033
Spain Precision Medicine Market Key Takeaways
- Market Size (2024): USD 1.41 Billion
- Market Forecast (2033): USD 4.18 Billion
- CAGR (2025–2033): 11.87%
- The Spanish government allocated €22 billion for R&D and healthcare innovation, up 50% from six years ago.
- The €2 billion PERTE Vanguard Health initiative enhances public–private partnerships and tech integration into precision healthcare.
- Pharmaceuticals contribute 1.5% to Spain’s GDP, generating 36,000+ direct and 150,000 indirect jobs.
- Collaboration between pharma companies and research institutes accelerates genomically targeted therapies.
Sample Request Link:- https://www.imarcgroup.com/spain-precision-medicine-market/requestsample
The Spanish government’s strong commitment to healthcare innovation is a major driver of the precision medicine market. With €22 billion dedicated to R&D, much of it channeled through PERTE Vanguard Health, Spain aims to expand public–private partnerships, upgrade healthcare infrastructure, and accelerate nationwide adoption of personalized medical solutions. This increased investment supports cutting-edge technologies such as genomics, bioinformatics, and AI-driven diagnostics, making precision medicine more accessible and scalable.
Spain’s pharmaceutical industry plays a pivotal role in advancing the precision medicine landscape. Contributing 1.5% to national GDP, the sector employs over 36,000 direct workers and 150,000 indirect professionals, reflecting its economic and scientific importance. Pharmaceutical companies are heavily involved in developing targeted therapies based on genetic and molecular patient profiles, leading to improved treatment outcomes and personalized care pathways.
Collaborations between pharmaceutical firms and public research institutions further reinforce Spain’s precision medicine progress. These partnerships translate scientific discoveries into real clinical applications, enabling patient access to personalized therapies and advanced diagnostic technologies. With strong governmental support, rising R&D activities, and an evolving innovation ecosystem, Spain is rapidly strengthening its position in the global precision medicine market.
Product Insights
- Consumables
- Instruments
- Services
Technology Insights
- Big Data Analytics
- Bioinformatics
- Gene Sequencing
- Drug Discovery
- Companion Diagnostics
- Others
Application Insights
- Oncology
- Central Nervous System (CNS)
- Immunology
- Respiratory Medicine
- Infections
- Others
End User Insights
- Hospitals and Clinics
- Diagnostics Centers
- Pharma and Biotech Companies
- Healthcare and IT Firms
- Others
Regional Insights
Northern Spain, Eastern Spain, Southern Spain, Central Spain
The report offers detailed forecasts for each region; however, dominant region or specific regional market share is not explicitly provided.
Recent Developments & News
- November 2024: QIAGEN relocated its QIAstat-Dx operations to a new site in Esplugues de Llobregat, strengthening its syndromic testing capabilities crucial for precision medicine.
- October 2024: Velsera partnered with Diagnostics Longwood to expand access to precision genomics through advanced NGS workflow integration across Spain and Portugal, supporting oncology and inherited disease diagnostics.
Key Players
- QIAGEN
- Velsera
- Diagnostics Longwood
If additional specific information is required, it will be delivered as part of the customization.
Request Customization:- https://www.imarcgroup.com/request?type=report&id=29278&flag=E
IMARC Group provides market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory navigation, licensing support, branding, marketing strategies, competitive benchmarking, pricing and cost analysis, and procurement research.
Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
India: +91 120 433 0800
United States: +1-201-971-6302
